BioNTech has presented promising early results from the neoantigen targeting cancer immunotherapy it is developing with Roche, as it seeks to advance its multi-pronged oncology ambitions.
Autogene cevumeran (also known as BNT122) uses BioNTech’s mRNA platform to deliver a cancer antigenthat that is individually tailored to each specific patient’s tumor
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?